{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T05:10:04Z","timestamp":1683177004543},"reference-count":91,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1157\/13076464","type":"journal-article","created":{"date-parts":[[2005,6,22]],"date-time":"2005-06-22T12:21:44Z","timestamp":1119442904000},"page":"65-74","source":"Crossref","is-referenced-by-count":15,"title":["Enfermedad pulmonar obstructiva cr\u00f3nica"],"prefix":"10.1016","volume":"125","author":[{"given":"Marc","family":"Miravitlles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13076464_bib1","first-page":"1278","article-title":"Geographical variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study","volume":"118","author":"Sobradillo","year":"2000","journal-title":"Chest"},{"key":"10.1157\/13076464_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1183\/09031936.01.00087101","article-title":"Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults","volume":"18","author":"Cerveri","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1157\/13076464_bib3","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1157\/13058851","article-title":"Estudio demogr\u00e1fico del tabaquismo en el \u00c1rea de Salud 5 de Valencia","volume":"40","author":"Peris Cardells","year":"2004","journal-title":"Arch Bronconeumol"},{"key":"10.1157\/13076464_bib4","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1378\/chest.123.3.784","article-title":"Costs of chronic bronchitis and COPD. A one year follow-up study","volume":"123","author":"Miravitlles","year":"2003","journal-title":"Chest"},{"key":"10.1157\/13076464_bib5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1157\/13056712","article-title":"Costes de la EPOC en Espa\u00f1a. Estimaci\u00f3n a partir de un estudio epidemiol\u00f3gico poblacional","volume":"40","author":"Masa","year":"2004","journal-title":"Arch Bronconeumol"},{"key":"10.1157\/13076464_bib6","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0300-2896(01)78820-5","article-title":"El coste de la enfermedad pulmonar obstructive cr\u00f3nica en Espa\u00f1a. Opciones para una optimizaci\u00f3n de recursos","volume":"37","author":"Miravitlles","year":"2001","journal-title":"Arch Bronconeumol"},{"key":"10.1157\/13076464_bib7","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0300-2896(15)30110-1","article-title":"Desarrollo y resultados de un programa de cribado de la EPOC en Atenci\u00f3n Primaria. El proyecto PADOC","volume":"36","author":"Miravitlles","year":"2000","journal-title":"Arch Bronconeumol"},{"key":"10.1157\/13076464_bib8","unstructured":"Office of the Surgeon General. Tobacco Cessation Guideline. Disponible en: www.surgeongeneral.gov\/tobacco\/default.htm"},{"key":"10.1157\/13076464_bib9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0300-2896(01)75089-2","article-title":"Recomendaciones para la atenci\u00f3n al paciente con enfermedad pulmonar obstructiva cr\u00f3nica","volume":"37","author":"\u00c1lvarez-Sala","year":"2001","journal-title":"Arch Bronconeumol"},{"key":"10.1157\/13076464_bib10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1378\/chest.125.1.249","article-title":"The role of long-acting bronchodilators in the management of stable COPD","volume":"125","author":"Tashkin","year":"2004","journal-title":"Chest"},{"key":"10.1157\/13076464_bib11","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1164\/ajrccm.155.4.9105068","article-title":"Quality of life changes in COPD patients treated with salmeterol","volume":"155","author":"Jones","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1157\/13076464_bib12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1183\/09031936.04.00072703","article-title":"Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease","volume":"24","author":"O\u2019Donnell","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1157\/13076464_bib13","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1136\/thx.2003.019620","article-title":"Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD","volume":"59","author":"Man","year":"2004","journal-title":"Thorax"},{"key":"10.1157\/13076464_bib14","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1183\/09031936.02.00240902","article-title":"Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial","volume":"19","author":"Aalbers","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1157\/13076464_bib15","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1164\/ajrccm.164.5.2007006","article-title":"Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease","volume":"164","author":"Dahl","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1157\/13076464_bib16","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1034\/j.1399-3003.2000.15e11.x","article-title":"Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium","volume":"15","author":"Van Noord","year":"2000","journal-title":"Eur Respir J"},{"key":"10.1157\/13076464_bib17","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1378\/chest.119.6.1661","article-title":"Salmeterol plus theophylline combination therapy in the treatment of COPD","volume":"119","author":"ZuWallack","year":"2001","journal-title":"Chest"},{"key":"10.1157\/13076464_bib18","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1378\/chest.119.5.1347","article-title":"In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium","volume":"119","author":"D\u2019Urzo","year":"2001","journal-title":"Chest"},{"key":"10.1157\/13076464_bib19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1164\/ajrccm.163.1.2004214","article-title":"Regular versus as-needed short-acting inhaled beta-agonist therapy for chronic obstructive pulmonary disease","volume":"163","author":"Cook","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1157\/13076464_bib20","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1183\/09031936.93.06060886","article-title":"Compliance with pulmonary medication in general practice","volume":"6","author":"Dekker","year":"1993","journal-title":"Eur Respir J"},{"key":"10.1157\/13076464_bib21","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1378\/chest.126.6.1946","article-title":"Tiotropium bromide","volume":"126","author":"Gross","year":"2004","journal-title":"Chest"},{"key":"10.1157\/13076464_bib22","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1164\/ajrccm.161.4.9903044","article-title":"Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease","volume":"161","author":"Littner","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1157\/13076464_bib23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/thorax.55.4.289","article-title":"A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease","volume":"55","author":"Van Noord","year":"2000","journal-title":"Thorax"},{"key":"10.1157\/13076464_bib24","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1183\/09031936.02.00238002","article-title":"Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease","volume":"19","author":"Van Noord","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1157\/13076464_bib25","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1378\/chest.124.5.1743","article-title":"Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes","volume":"124","author":"Celli","year":"2003","journal-title":"Chest"},{"key":"10.1157\/13076464_bib26","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1183\/09031936.04.00116004","article-title":"Effects of tiotropium on lung hyperinflation, dyspnoea and exercise ntolerance in COPD","volume":"23","author":"O\u2019Donnell","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1157\/13076464_bib27","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/thorax.58.5.399","article-title":"Health outcomes following six months treatment with once daily tiotropium compared to twice daily salmeterol in patients with COPD","volume":"58","author":"Brusasco","year":"2003","journal-title":"Thorax"},{"key":"10.1157\/13076464_bib28","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1136\/thx.53.4.269","article-title":"Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonay disease","volume":"53","author":"Tsukino","year":"1998","journal-title":"Thorax"},{"key":"10.1157\/13076464_bib29","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1164\/rccm.2105106","article-title":"Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease","volume":"165","author":"Culpitt","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1157\/13076464_bib30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/thx.53.2.129","article-title":"Structural and inflammatory changes in COPD: a comparison with asthma","volume":"53","author":"Jeffery","year":"1998","journal-title":"Thorax"},{"key":"10.1157\/13076464_bib31","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0140-6736(04)15650-X","article-title":"Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase","volume":"363","author":"Barnes","year":"2004","journal-title":"Lancet"},{"key":"10.1157\/13076464_bib32","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/bmj.320.7245.1297","article-title":"Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial","volume":"320","author":"Burge","year":"2000","journal-title":"BMJ"},{"key":"10.1157\/13076464_bib33","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1056\/NEJM199906243402503","article-title":"Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking","volume":"340","author":"Pauwels","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1157\/13076464_bib34","doi-asserted-by":"crossref","first-page":"969","DOI":"10.7326\/0003-4819-138-12-200306170-00008","article-title":"Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis","volume":"138","author":"Highland","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1157\/13076464_bib35","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/thorax.58.11.937","article-title":"Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis","volume":"58","author":"Sutherland","year":"2003","journal-title":"Thorax"},{"key":"10.1157\/13076464_bib36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/thx.54.1.7","article-title":"Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease:a meta-analysis","volume":"54","author":"Van Grunsven","year":"1999","journal-title":"Thorax"},{"key":"10.1157\/13076464_bib37","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1183\/09031936.93.06060868","article-title":"Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV1 during long-term inhaled conticosteroid treatment","volume":"6","author":"Kerstjens","year":"1993","journal-title":"Eur Respir J"},{"key":"10.1157\/13076464_bib38","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0002-9343(02)01143-9","article-title":"The effect of inhaled corticosteroids in chronic obstructive pulmonary disease:a systematic review of randomized placebo-controlled trials","volume":"113","author":"Alsaeedi","year":"2002","journal-title":"Am J Med"},{"key":"10.1157\/13076464_bib39","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1183\/09031936.03.00013303","article-title":"Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations","volume":"21","author":"Jones","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1157\/13076464_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/09031936.03.00063703","article-title":"Global strategy for the diagnosis, management and prevention of COPD:2003 update","volume":"22","author":"Fabbri","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1157\/13076464_bib41","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1378\/chest.126.6.1815","article-title":"Efficacy of inhaled steroids in undiagnosed subjects at risk for COPD","volume":"126","author":"Albers","year":"2004","journal-title":"Chest"},{"key":"10.1157\/13076464_bib42","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1378\/chest.126.1.213","article-title":"The local side effects of inhaled corticosteroids","volume":"126","author":"Roland","year":"2004","journal-title":"Chest"},{"key":"10.1157\/13076464_bib43","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1164\/rccm.200206-606OC","article-title":"Inhaled corticosteroids and hip fracture. A population-based case-control study","volume":"166","author":"Hubbard","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1157\/13076464_bib44","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1164\/rccm.2112055","article-title":"Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease","volume":"166","author":"Mahler","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1157\/13076464_bib45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1378\/chest.122.1.47","article-title":"A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol","volume":"122","author":"Donohue","year":"2002","journal-title":"Chest"},{"key":"10.1157\/13076464_bib46","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(03)12459-2","article-title":"Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a rendomised controlled trial","volume":"361","author":"Calverley","year":"2003","journal-title":"Lancet"},{"key":"10.1157\/13076464_bib47","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1183\/09031936.03.00031402","article-title":"Efficacy and safety of budesonide\/formoterol in the management of chronic obstructive pulmonary disease","volume":"21","author":"Szafranski","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1157\/13076464_bib48","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1183\/09031936.03.00027003","article-title":"Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease","volume":"22","author":"Calverley","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1157\/13076464_bib49","first-page":"34","article-title":"\u00bfSe debe revisar el concepto de EPOC y bronquitis cr\u00f3nica?","volume":"58","author":"Miravitlles","year":"2000","journal-title":"JANO"},{"key":"10.1157\/13076464_bib50","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1001\/jama.290.17.2301","article-title":"Contemporary management of chronic obstructive pulmonary disease","volume":"290","author":"Sin","year":"2003","journal-title":"JAMA"},{"key":"10.1157\/13076464_bib51","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1378\/chest.126.1.220","article-title":"Inhalde combination therapy with long-acting beta2-agonists and corticosteroids in satble COPD","volume":"126","author":"Cazzola","year":"2004","journal-title":"Chest"},{"key":"10.1157\/13076464_bib52","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1053\/rmed.2002.1455","article-title":"Bronchodilator effect of an inhlade combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD","volume":"97","author":"Cazzola","year":"2003","journal-title":"Respir Med"},{"key":"10.1157\/13076464_bib53","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0025-7753(02)73396-4","article-title":"El fracaso en el tratamiento de las agudizaciones de la enfermedad pulmonar obstructiva cr\u00f3nica. Factores de riesgo e importancia cl\u00ednica","volume":"119","author":"Miravitlles","year":"2002","journal-title":"Med Clin (Barc)"},{"key":"10.1157\/13076464_bib54","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1183\/09031936.02.00301302","article-title":"Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice","volume":"20","author":"Soriano","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1157\/13076464_bib55","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1183\/09031936.04.00062504","article-title":"Inhaled steroids and mortality in COPD: bias from unaccounted immortal time","volume":"23","author":"Suissa","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1157\/13076464_bib56","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1183\/09031936.04.00120603","article-title":"The TORCH (towards a revolution in COPD health) survival study protocol","volume":"24","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1157\/13076464_bib57","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.rmed.2003.12.012","article-title":"PDE4 inhibitors in COPD-a more selective approach to treatment","volume":"98","author":"Vignola","year":"2004","journal-title":"Respir Med"},{"key":"10.1157\/13076464_bib58","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/thorax.58.7.573","article-title":"Effect of cilomilast (Ariflo) on TNF-\u03b1, IL-8, and GM-CSF release by airway cells of patients with COPD","volume":"58","author":"Profita","year":"2003","journal-title":"Thorax"},{"key":"10.1157\/13076464_bib59","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0140-6736(01)05481-2","article-title":"Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study","volume":"358","author":"Compton","year":"2001","journal-title":"Lancet"},{"key":"10.1157\/13076464_bib60","first-page":"280","article-title":"In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor","volume":"297","author":"Bundschuh","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1157\/13076464_bib61","first-page":"A518","article-title":"Roflumilast, a novel, selective phosphodiesterase 4 inhibitor, improves lung function in patients with moderate to severe COPD","volume":"169","author":"Rabe","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1157\/13076464_bib62","first-page":"A602","article-title":"Roflumilast, a novel, selective phosphodiesterase 4 inhibitor, improves quality of life and lowers exacerbation rate in patients with moderate to severe COPD","volume":"169","author":"O\u2019Donnell","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1157\/13076464_bib63","first-page":"A596","article-title":"Safety profile of roflumilast, a novel, selective phosphodiesterase 4 inhibitor, in patients with moderate to severe COPD","volume":"169","author":"Bateman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1157\/13076464_bib64","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1183\/09031936.03.00046203","article-title":"Montelukast attenuates the airway response to hypertonic saline in moderate-to-severe COPD","volume":"22","author":"Z\u00fchlke","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1157\/13076464_bib65","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1378\/chest.122.1.289","article-title":"A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD","volume":"122","author":"Gompertz","year":"2002","journal-title":"Chest"},{"key":"10.1157\/13076464_bib66","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.rmed.2003.09.003","article-title":"Long-term montelukast therapy in moderate to severe COPD-a preliminary observation","volume":"98","author":"Rubinstein","year":"2004","journal-title":"Respir Med"},{"key":"10.1157\/13076464_bib67","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1159\/000050550","article-title":"Comparison of the bronchodilating affect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease","volume":"68","author":"Cazzola","year":"2001","journal-title":"Respiration"},{"key":"10.1157\/13076464_bib68","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1378\/chest.126.3.926","article-title":"Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD","volume":"126","author":"Mahler","year":"2004","journal-title":"Chest"},{"key":"10.1157\/13076464_bib69","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0954-6111(99)90004-5","article-title":"Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice","volume":"93","author":"Miravitlles","year":"1999","journal-title":"Respir Med"},{"key":"10.1157\/13076464_bib70","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0300-2896(15)30274-X","article-title":"Tratamiento de la bronquitis cr\u00f3nica y la EPOC en Atenci\u00f3n Primaria","volume":"35","author":"Miravitlles","year":"1999","journal-title":"Arch Bronconeumol"},{"key":"10.1157\/13076464_bib71","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1157\/13047332","article-title":"Tratamiento farmacol\u00f3gico de la EPOC en dos niveles asistenciales. Grado de adecuaci\u00f3n a las normativas recomendadas","volume":"39","author":"De Miguel","year":"2003","journal-title":"Arch Bronconeumol"},{"key":"10.1157\/13076464_bib72","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1034\/j.1399-3003.2000.16b12.x","article-title":"The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review","volume":"16","author":"Stey","year":"2000","journal-title":"Eur Respir J"},{"key":"10.1157\/13076464_bib73","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1183\/09031936.01.17303290","article-title":"The bronchitis randomized on NAC cost-utility study (BRONCUS): hypothesis and design","volume":"17","author":"Decramen","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1157\/13076464_bib74","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/bmj.322.7297.1271","article-title":"Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: a systematic review","volume":"322","author":"Poole","year":"2001","journal-title":"BMJ"},{"key":"10.1157\/13076464_bib75","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.pupt.2003.08.004","article-title":"Effect of twelvemonths therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST trial)","volume":"17","author":"Malerba","year":"2004","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1157\/13076464_bib76","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1378\/chest.126.5.1645","article-title":"Oral purified bacterial extracts in chronic bronchitis and COPD","volume":"126","author":"Steurer-Stey","year":"2004","journal-title":"Chest"},{"key":"10.1157\/13076464_bib77","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1164\/ajrccm.153.1.8542136","article-title":"Subcutaneous administration of hyaluronan reduces the number of infectious exacerbations in patients with chronic bronchitis","volume":"153","author":"Venge","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1157\/13076464_bib78","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000196674","article-title":"Effectiveness of immunomodulating treatment (Thymostimulin) in chronic obstructive pulmonary disease","volume":"64","author":"Ba\u00f1os","year":"1997","journal-title":"Resp\u00ecration"},{"key":"10.1157\/13076464_bib79","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1164\/ajrccm.163.7.2002015","article-title":"Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycophosphopeptical (Inmunoferon)","volume":"163","author":"Prieto","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1157\/13076464_bib80","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1378\/chest.127.4.1212","article-title":"Treatment with the immunomodulator AM3 (inmunoferon) improves the health-related quality of life of patients with chronic obstructive pulmonary disease","volume":"127","author":"\u00c1lvarez-Mon","year":"2005","journal-title":"Chest"},{"key":"10.1157\/13076464_bib81","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nm0697-675","article-title":"Retinoid acid treatment abrogates elastase-induced pulmonary emphysema in rats","volume":"3","author":"Masaro","year":"1997","journal-title":"Nat Med"},{"key":"10.1157\/13076464_bib82","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1164\/ajrccm.165.5.2106123","article-title":"A pilot study of all-trans-retinoic acid for the treatment of human emphysema","volume":"165","author":"Mao","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1157\/13076464_bib83","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1378\/chest.115.4.957","article-title":"Efficacy of salmeterol xinafoate in the treatment of COPD","volume":"115","author":"Mahler","year":"1999","journal-title":"Chest"},{"key":"10.1157\/13076464_bib84","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1183\/09031936.02.00238702","article-title":"Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium","volume":"19","author":"Vincken","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1157\/13076464_bib85","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1053\/rmed.2002.1425","article-title":"Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation","volume":"97","author":"Jones","year":"2003","journal-title":"Respir Med"},{"key":"10.1157\/13076464_bib86","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1183\/09031936.03.00083703","article-title":"One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease","volume":"23","author":"Oostenbrink","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1157\/13076464_bib87","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0149-2918(03)90039-7","article-title":"An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease","volume":"25","author":"Hogan","year":"2003","journal-title":"Clin Ther"},{"key":"10.1157\/13076464_bib88","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.rmed.2004.05.003","article-title":"The functional impact of adding salmeterol and tiotropium in patients with stable COPD","volume":"98","author":"Cazzola","year":"2004","journal-title":"Respir Med"},{"key":"10.1157\/13076464_bib89","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pupt.2003.09.001","article-title":"The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD","volume":"17","author":"Cazzola","year":"2004","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1157\/13076464_bib90","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1023\/A:1015520110663","article-title":"Treatment and quality of life in patients with chronic obstructive pulmonary disease","volume":"11","author":"Miravitlles","year":"2002","journal-title":"Qual Life Res"},{"key":"10.1157\/13076464_bib91","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1183\/09031936.02.01302001","article-title":"Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease","volume":"20","author":"Miravitlles","year":"2002","journal-title":"Eur Respir J"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775305719461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775305719461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T13:27:13Z","timestamp":1683120433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775305719461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":91,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S0025775305719461"],"URL":"https:\/\/doi.org\/10.1157\/13076464","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}